Hinova Pharmaceuticals's quarterly market cap
declined
from Sep. 2025 (¥5,272.60 Mil) to Dec. 2025 (¥4,868.62 Mil) and
declined
from Dec. 2025 (¥4,868.62 Mil) to Mar. 2026 (¥4,358.68 Mil).
Hinova Pharmaceuticals's annual market cap
declined
from Dec. 2023 (¥5,155.76 Mil) to Dec. 2024 (¥3,040.78 Mil) but then
increased
from Dec. 2024 (¥3,040.78 Mil) to Dec. 2025 (¥4,868.62 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Hinova Pharmaceuticals's Enterprise Value for Today is ¥3,288.42 Mil.
Hinova Pharmaceuticals (SHSE:688302) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688302 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Hinova Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hinova Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hinova Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Hinova Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Hinova Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hinova Pharmaceuticals (SHSE:688302) has a Market Cap of ¥4,011.12 Mil as of Jul. 05, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Hinova Pharmaceuticals and its competitors. According to the industry distribution chart, Hinova Pharmaceuticals ranks #388 out of 1422 companies in the Biotechnology industry, placing it in the top 27.3%.
Is Hinova Pharmaceuticals' Market Cap too high?
Hinova Pharmaceuticals' current Market Cap is ¥4,011.12 Mil. Based on the distribution chart, Hinova Pharmaceuticals ranks #388 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Hinova Pharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Hinova Pharmaceuticals' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hinova Pharmaceuticals ranks #388 out of 1422 companies for Market Cap. This puts Hinova Pharmaceuticals in the upper half of its industry. The industry median Market Cap is 121.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.26, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Hinova Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 121.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hinova Pharmaceuticals's current Market Cap is ¥4,011.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hinova Pharmaceuticals stock overvalued right now?
Hinova Pharmaceuticals (SHSE:688302) has a current Market Cap of ¥4,011.12 Mil. The current Market Cap is ¥4,011.12 Mil. Hinova Pharmaceuticals' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Hinova Pharmaceuticals (SHSE:688302), the current Market Cap is ¥4,011.12 Mil as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
26GF Score
Get the complete analysis for SHSE:688302
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688302 has been successfully added to your 
